Abstract
Long Intergenic Non-Protein Coding RNA 511 (LINC00511) is an RNA gene being mostly associated with lung cancer. Further assessments have shown dysregulation of this lncRNA in a variety of cancers. LINC00511 has interactions with hsa-miR-29b-3p, hsa-miR-765, hsa-mir-150, miR-1231, TFAP2A-AS2, hsa-miR-185-3p, hsa-miR-29b-1-5p, hsa-miR-29c-3p, RAD51-AS1 and EZH2. A number of transcription factors have been identified that regulate expression of LINC00511. The current narrative review summarizes the role of LINC00511 in different cancers with an especial focus on its prognostic impact in human cancers.
Introduction
Long non-coding RNAs (lncRNAs) are widely expressed transcripts with essential roles in gene regulation. Based on the results of the Human GENCODE project, the number of lncRNA genes in the human genome is estimated to surpass 16,000 (Fang et al., 2018). These transcripts embrace lncRNAs transcribed by RNA polymerase II, gene-overlapping antisense transcripts as well as lncRNAs from intergenic regions (lincRNAs) (Ghafouri-Fard et al., 2020; Ghafouri-Fard et al., 2021; Statello et al., 2021). Typically, lncRNAs have a 7-methyl guanosine cap at the 5′end and a polyadenylated tail at the 3′ends. Moreover, lncRNAs are spliced in a similar manner to mRNAs (Statello et al., 2021). However, several RNA polymerase II-transcribed lncRNAs are incompetently processed and are held in the nuclear compartment (Statello et al., 2021). LncRNAs interact with DNA, RNA and proteins. Through these interactions, lncRNAs influence chromatin structure and function, affect the assembly of nuclear bodies, change the stability and expression of mRNAs within the cytoplasm and regulate signaling pathways (Statello et al., 2021; Hussen et al., 2022). In comparison with mRNA promoters, lincRNA promoters have been found to be devoid of transcription factor binding sites, but having binding sites for a number of specific factors such as GATA and FOS (Melé et al., 2017).
Long Intergenic Non-Protein Coding RNA 511 (LINC00511) is an RNA gene being mostly associated with lung cancer. This lncRNA is encoded on chr17:72,290,091-72,640,472 (GRCh38/hg38), minus strand. Notably, more than 100 alternatively splice variants have been recognized for LINC00511. Except for two variants with retained introns (LINC00511-279 with 3766 bp and LINC00511-278 with 508 bp), other are affiliated with lncRNA group of transcripts (https://asia.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000227036; r=17:72290091-72640472). This lncRNA has important roles in the development of cancers and can be used as a possible diagnostic and prognostic marker in cancer. Abnormal expression of LINC00511 in a wide array of malignancies potentiates it as a target for therapeutic interventions. Based on DIANA-LncBase database (https://diana.e-ce.uth.gr/lncbasev3) (Karagkouni et al., 2020), expression of LINC00511 in various tissues and cell types have been investigated. With medium and high TPM levels and in homosapiens, the highest level of expression of LINC00511 is in prostate tissue and PC3 cell type along with cancer/malignant category.
The current narrative review summarizes the role of LINC00511 in different cancers with an especial focus on its prognostic impact in human cancers.
LINC00511 in cancers
Several studies have reported dysregulation (mainly upregulation) of LINC00511 in different cancers. These studies have also identified miRNAs that are sponged by LINC00511.
Breast cancer
In breast cancer, LINC00511 has been found to be highly expressed in the clinical samples and its over-expression has been correlated with poor prognosis (Lu et al., 2018). Functional studies have shown that LINC00511 promotes proliferation, sphere-formation capacity, expression of stem factors and growth of breast tumors (Lu et al., 2018). From a mechanical point of view, LINC00511 acts as a molecular sponge for miR-185-3p to enhance expression of E2F1 protein. Besides, E2F1 binds with the promoter of Nanog gene and increases its expression (Figure 1). Therefore, LINC00511/miR-185-3p/E2F1/Nanog axis has been identified as an important route for induction of stemness and tumorigenesis in breast cancer (Lu et al., 2018). Another study in breast cancer has revealed more than 180 potential targets for LINC00511 through siRNA and RNA-seq assays. Bioinformatics analyses have shown relation between differently expressed genes and signaling pathways mediated by p38-α and p38-β. LINC00511 has been found to be mainly located in the cytoplasm regulating expression of MMP13 through sponging miR-150 (Shi et al., 2021). Expression of LINC00511 in breast cancer samples has been closely correlated with the presence of lymph node metastasis, greater tumor size and molecular subtypes of breast cancer. This lncRNA has been found to increase migratory potential and invasive ability of MDA-MB-231 and MCF-7 cells. Moreover, expression of LINC00511 has been shown to be increased by DNA hypomethylation. In turn, LINC00511 could promote expressions of Wnt10A, E2F2, TGFA, and MET and reduce sensitivity of breast cancer cells to Panobinostat (Liu et al., 2021a). LINC00511 can also influence the cytotoxic effects of paclitaxel on breast cancer cells through regulating miR-29c/CDK6 axis (Zhu et al., 2019).
FIGURE 1
Another study in patients with breast cancer has reported upregulation of LINC00511 and miR-301a-3p in patients’ blood parallel with downregulation of miR-185-3p (Mahmoud et al., 2021). Notably, LINC00511 expression has been increased in early stages of breast cancer. Area under the reciever operating characteristic curves of LINC00511, miR-185-3p, and miR-301a-3p has been superior to classical tumor markers indicating the diagnostic values of these transcripts as molecular biomarkers in liquid biopsy. Moreover, expression of LINC00511 has been correlated with lymph node metastasis and advanced tumor grades (Mahmoud et al., 2021). Additionally, the sponging effect of LINC00511 on miR-185 has been shown to be involved in breast cancer recurrence and radioresistance via regulation of STXBP4 expression (Liu et al., 2019). In breast cancer cells, LINC00511 expression induced by TFAP-2 expression and directly affected by ER deficiency at the transcriptional level. Through its interaction with EZH2, LINC00511 has been shown to encourage tumor development and suppress apoptosis (Figure 2) (Zhang et al., 2019). Table 1 summarizes the results of studies regarding the role of this lncRNA in breast cancer.
FIGURE 2
TABLE 1
| Cancer type | Expression/Role | Samples/Assessed cell lines | Pathways | Targets/Regulators | Function | Ref |
|---|---|---|---|---|---|---|
| Breast Cancer (BC) | Upregulated/Oncogene | 39 cases of breast cancer/MCF-10A, MDA-MB-468, MDA-MB-231, MDA-MB-453, MCF-7 | miR-185-3p/E2F1/Nanog axis | miR-185-3p/E2F1 | LINC00511/miR-185-3p/E2F1/Nanog axis has a role in breast cancer stemness and malignancy | Lu et al. (2018) |
| Upregulated/Oncogene | 10 TNTPs/MDA-MB-231, MCF-7 | LINC00511/miR-150/MMP13 axis | miR-150/MMP13 | The LINC00511/miR-150/MMP13 axis could represent a novel treatment strategy for sufferers with breast cancer, because it is a breast cancer promoter | Shi et al. (2021) | |
| Upregulated/Oncogene | MDA-MB-231, MCF-7, T47D, MDA-MB-468, MCF-10a | - | MET, E2F2, TGFA, and WNT10A | Patients with breast cancer who express LINC00511 more than usual have a bad outcome. Breast cancer progression is facilitated by LINC00511 | Liu et al. (2021a) | |
| Upregulated/Oncogene | 21 TNTPs/MDA-MB-231, MCF-7, Hs-578T, T47D, MCF-10A | LINC00511/miR-29c/CDK6 axis | miR-29c/CDK6 | Through controlling the miR-29c/CDK6 axis, LINC00511 lowering increased paclitaxel cytotoxicity in BC cells. A viable BC therapeutic option might be LINC005111 | Zhu et al. (2019) | |
| Upregulated/Oncogene | 25 patients and 25 control samples | LINC00511/miR-185-3p axis | miR-301a-3p | A more accurate diagnosis of BC may be made using serum LINC00511 and miR-301a-3p as prospective molecular indicators | Mahmoud et al. (2021) | |
| Upregulated/Oncogene | MDA-MB-231, MDA-MB-436 | LINC00511/miR-185/STXBP4 axis | miR-185/STXBP4 | Inhibition of LINC00511 reduces It has ability to bind competitively to miR-185, which boosts STXBP4 production and enhances radiation responsiveness in BC. A prospective treatment approach for boosting the prognosis of BC is the LINC00511/miR-185/STXBP4 axis | Liu et al. (2019) | |
| Upregulated/Oncogene | - | Apoptosis pathway | - | Through the suppression of antiapoptotic genes, LINC00511 deletion procedures using CRISPR/Cas9 improved the apoptosis of breast cancer cells | Azadbakht et al. (2022) | |
| Upregulated/Oncogene | MCF7, UACC-812, MDA-MB-231 | - | EZH2 and CDKN1B | In ER-negative breast cancer, lncRNAs have a role in controlling the network of cell cycle regulation, and this has led to speculation that LINC00511 may be used as an anticancer treatment | Zhang et al. (2019) | |
| Upregulated/Oncogene | 15 TNTPs | LINC00511/hsa-miR-573/GSDMC axis | miR-573/GSDMC | The most probable ncRNA-related mechanisms that drive GSDMC in BRCA are thought to be the LINC00511/hsa-miR-573 axis | Sun et al. (2022) | |
| Upregulated/Oncogene | 7 TNTPs (HER-2-enriched) | - | - | A putative chemical indicator and viable treatment option for breast cancer of the HER-2-enriched subgroup is LINC00511 | Yang et al. (2016) |
Role of LINC00511 in breast cancer.
Gastric cancer
LINC00511 has been shown to promote progression of gstaric acnecr through regulating SOX4 expression and epigenetically suppressing PTEN to induce activity of PI3K/AKT pathway (Wang et al., 2021). Moreover, LINC00511 can promote growth of gastric tumors through acting as a molecular sponge for miR-124-3p and regulating expression of PDK4 (Sun et al., 2020a). miR-515-5p is another miRNA that is sponged by LINC00511 in gastric cancer cells leading to enhancemnet of proliferation and invasion of these cells (Wang et al., 2020a). Finally, miR-625-5p/NFIX (Chen et al., 2019a), miR-124-3p/EZH2 (Huang et al., 2020), miR-625-5p/STAT3 (Cui et al., 2021) and miR-29b/KDM2A (Zhao et al., 2020) are other molecular axes regulated by LINC00511 in gastric cancer. Table 2 shows the role of LINC00511 in gastric cancer.
TABLE 2
| Cancer type | Expression/Role | Samples/Assessed cell lines | Pathways | Targets/Regulators | Function | Ref |
|---|---|---|---|---|---|---|
| Gastric Cancer (GC) | Upregulated/Oncogene | AGS, HGC‐27, ACP01, SNU‐1, Het‐1A | PI3K/AKT pathway | miR‐195‐5p/SOX4 | After epigenetically suppressing PTEN to activate the PI3K/AKT pathway by engaging EZH2, SOX4-induced LINC00511 stimulated SOX4 via ceRNA pattern, promoting GC cell proliferation, migration and stemness while preventing GC cell death | Wang et al. (2021) |
| Upregulated/Oncogene | MKN-45, BGC-823, HGC-27, MGC-803, GES-1 | LINC00511/miR-124-3p/PDK4 axis | miR-124-3p/PDK4 | By functioning as a ceRNA to control the miR-124-3p/PDK4 axis, which could be a viable therapeutic option for GC, LINC00511 encourages the tumor cell growth | Sun et al. (2020a) | |
| Upregulated/Oncogene | 25 patients with gastric cancer/GES-1, AGS, SGC7901, BGC823, MKN45, MGC803 | MAPK signaling pathway | miR-515-5p | By influencing miR-515-5p, LINC00511 can stimulate the expansion of tumor cells, suggesting that it might be a viable option for the creation of anti-cancer medications | Wang et al. (2020a) | |
| Upregulated/Oncogene | 35 TNTPs/GES1, GC27, BGC823, MGC803, SGC7901 | LINC00511/miR-625-5p/NFIX axis | miR-625-5p/NFIX | By targeting NFIX in GC cells, LINC00511 is a tumor activator to sponge miR-625-5p. Elimination of this lncRNA might be viewed as a treatment option for GC therapy | Chen et al. (2019a) | |
| Upregulated/Oncogene | 80 patients with GC/GES-1, MGC, HGC, MKN25, MKN28 | LINC00511/miR-124-3p/EZH2 pathway | miR-124-3p/EZH2 pathway | In sufferers with GC, LINC00511 is linked to a poor overall survival. It was predicted that LINC00511 would be a suitable target for treating human GC since it has a function in encouraging the cancerous cells growth | Huang et al. (2020) | |
| Upregulated/Oncogene | 50 TNTPs/MKN28, BGC-823, MKN-45, MGC-803, SGC-7901, GES-1 | STAT3 signal pathway | miR-625-5p/STAT3 | By controlling miR-625-5p and STAT3, LINC00511 encourages GC cell growth, implying that LINC00511 has oncogenic capabilities that influence the formation of GC. | Cui et al. (2021) | |
| Upregulated/Oncogene | AGS, SGC7901 | LINC00511/miR-29b/KDM2A axis | miR-29b/KDM2A axis | In GC, LINC00511 depletion boosted the apoptosis and hindered cell growth. It is possible to exploit the LINC00511/miR-29b/KDM2A axis as a viable treatment option for GC. | Zhao et al. (2020) |
Role of LINC00511 in gastric cancer.
Lung cancer
LINC00511 has ben shown to promote proliferation, invasive capacities, and migration of non-small cell lung cancer cells through regulating miR-625-5p/GSPT1 axis (Cheng et al., 2021). Moreover, LINC00511 can promote progression of this type of cancer through binding to EZH2 and LSD1 and decreasing expression levels of LATS2 and KLF2 (Zhu et al., 2019). Besides, this lncRNA has a role in induction of tumor recurrence in this type of cancer through sponging miR-98-5p and increasing expression of TGFBR1 (Li et al., 2022). LINC00511 can also induce resistance of lung cancer cells to cisplatin through sponging miR-625 and influencing expression of LRRC8E (Liu et al., 2022). Finally, this lncRNA exerts its oncogenic effects in lung cancer through binding to EZH2 and decaresing expression of p57 (Sun et al., 2016). Table 3 shows the role of LINC00511 in lung cancer.
TABLE 3
| Cancer type | Expression/Role | Samples/Assessed cell lines | Pathways | Targets/Regulators | Function | Ref |
|---|---|---|---|---|---|---|
| Lung Squamous Cell Carcinoma (LUSC) | Upregulated/Oncogene | SK-MES-1, H226, 16-HBE | LINC00511/miR-150-5p/TADA1 axis | miR-150-5p/TADA1 | A plan for the therapeutic targeting of LINC00511 in LUSC should be developed, because it stimulates the advancement of LUSC. | Wu et al. (2020) |
| Lung Adenocarcinoma (LUAD) | Upregulated/Oncogene | 45 LAC tissues and corresponding adjacent normal lung tissues/BEAS‐2B, H1299, A549 | PKM2 signaling pathway | miR-625-5p/PKM2 | By influencing miR-625-5p/PKM2, LINC00511 was found to be engaged in the evolution of LAC, demonstrating that LINC00511/miR-625-5p/PKM2 may represent interesting treatment targets for LUAC. | Xue and Zhang (2020) |
| Upregulated/Oncogene | 40 TNTPs/A549, Calu-3, BEAS-2B, DV-90, PC-9 | LINC00511/miR-195-5p/GCNT3 axis | miR-195-5p/GCNT3 | By suppressing miR-195-5p, LINC00511 reduction encourages GCNT3 production, and as a result, supports the malignant growth of LUAD. | Zhang et al. (2022) | |
| Upregulated/Oncogene | A549/DDP, 16HBE | LINC00511/miR-182/BIRC5 axis | miR-182-3p/BIRC5 | After injection of cisplatin (DDP), LINC00511 silencing prevents the growth of A549/DDP cells into tumors. In order to understand the mechanism of gained DDP tolerance, this research offers a unique LINC00511/miR-182/BIRC5 model | Zhu et al. (2022) | |
| Upregulated/Oncogene | 35 TNTPs/A549, PC9, BEAS-2B | Linc00511/miR-126-5p/miR-218-5p/COL1A1 axis, PIK3/AKT pathway | miR-126-5p, miR-218-5p/COL1A1 | By targeting miR-126-5p and miR-218-5p, LINC00511 influences COL1A1 production, encouraging cancerous cell growth and motility. LINC00511 could be a viable treatment approach for LUAD. | Wang et al. (2022) |
Role of LINC00511 in lung cancer.
Other types of cancers
Over-expression of LINC00511 has been reported in a variety of cancers including colorectal, pancreatic, liver, thyroid and other types of cancers (Table 4).
TABLE 4
| Cancer type | Expression/Role | Samples/Assessed cell lines | Pathways | Targets/Regulators | Function | Ref |
|---|---|---|---|---|---|---|
| Hepatocellular Carcinoma (HCC) | Upregulated/Oncogene | Huh7, Hep3B | - | RAB27B | There seems to be a link between the creation of invadopodia and the generation of exosomes and LINC00511 dysregulation. In HCC, LINC00511 could be a treatment option | Peng et al. (2021) |
| Upregulated/Oncogene | SMCC7721, HepG2, Huh7, Hep3B | LINC00511/miR195/EYA1 axis | miR195/EYA1 | A prospective therapeutic option for the detection of HCC has been provided by LINC00511 that interacted with EYA1 to accelerate HCC formation through miR-195 | Hu et al. (2020a) | |
| Upregulated/Oncogene | 127 TNTPs/LO2, Hep3B, HepG2, SMMC-7721, MHCC97H, Huh7, HCCLM3 | - | miR-424 | LINC00511 may have a significant impact on how HCC develops, and that it will also act as a viable prognostic and therapeutic target. | Wang et al. (2019a) | |
| Liver Hepatocellular Carcinoma (LIHC) | Upregulated/Oncogene | LO2, MHCC-97H, Huh7, HCC-LM3, Hep3B, MHCC-97L, Huh6 | - | miRNA-29c | Through boosting tumor cell proliferative ability, LINC00511 worsens LIHC’s development. A predictive marker for LIHC could be LINC00511 | Liu et al. (2019) |
| Osteosarcoma (OS) | Upregulated/Oncogene | 24 TNTPs/SW1353, U2OS | LINC00511/miR-185-3p/E2F1 axis | miR-185-3p/E2F1 | As an oncogenic RNA, LINC00511 leads to the formation and spread of tumor cells. The LINC00511/miR-185-3p/E2F1 axis may be extremely important for the onset of osteosarcoma | Xu et al. (2020) |
| Upregulated/Oncogene | 30 TNTPs s/(MG‐63, Saos‐2, U2OS, HOS, NHOst | - | miR‐765 | Via substantially controlling the production of miR-765, aberrant transcription of LINC00511 boosted osteosarcoma cell tumorigenesis and motility | Yan et al. (2018) | |
| Downregulated/Tumor suppressor gene | 45 patients with osteosarcoma/hFOB1.19, MG-63, U‐2OS, Saos‐2, HOS | - | - | Elevated amounts of LINC00511 slow the growth of tumors. LINC00511 could be a new indicator and prospective osteosarcoma treatment approach | Qiao et al. (2020) | |
| Upregulated/Oncogene | 10 TNTPs/hFOB 1.19, MG-63, HOS, Saos-2, 143B | LINC00511/miRNA- 618/MAEL axis | miRNA- 618/MAEL | OS cell growth and malignancy were both hindered by lower LINC00511 production. It could be a viable biomarker for more exploration on the treatment of OS. | Guo et al. (2019) | |
| T-cell Acute Lymphoblastic Leukemia (T-ALL) | Upregulated/Oncogene | Blood samples of 35 T-ALL patients and 30 normal controls/HPB-ALL, TALL-1, ALL-SIL, CUTLL1, PBMC | LINC00511/miR-195-5p/LRRK1 axis | miR-195-5p/LRRK1 | Through the miR-195-5p/LRRK1 axis, LINC00511 accelerated the evolution of T-ALL, pointing a possible therapeutic hint for the T-ALL sufferers | Li et al. (2020) |
| Glioma | Upregulated/Oncogene | HEB, NHA, T98 G cells (CRL-1690), A172 cells (CRL-1620), LN229 cells (CRL-2611), U-87MG cells (HTB-14IG) | LINC00511/miR-15a-5p/AEBP1 axis | miR-15a-5p/AEBP1 | Glioma formation can be slowed down by LINC00511 knockdown. Additionally, via the miR-15a-5p/AEBP1 axis, the process of LINC00511 influences the onset of glioma | Liu et al. (2021b) |
| Upregulated/Oncogene | U87, U251, SHG44, A172, NHA | SP1/LINC00511/miR‐124‐3p/CCND2 axis | miR‐124‐3p/CCND2 | The transcription factor SP1 served as the inspiration for the overexpression of LINC00511 in glioma cells. Additionally, the upregulation of LINC00511 competitively sponges the miR-124-3p, driving the production of CCND2 and the cyclin D2 protein produced by this gene, which may hold significant potential for glioma therapies | Li et al. (2019) | |
| Papillary Thyroid Carcinoma (PTC) | Upregulated/Oncogene | 41 TNTPs/B-CPAP, KTC-1, KTC-1 | - | CDKs and EZH2 | As an oncogene in PTC, LINC00511 promotes proliferation through CDKs. It will serve as a fundamental therapeutic target for PTC. | Xiang et al. (2020) |
| Colorectal Cancer (CRC) | Upregulated/Oncogene | 85 CRC tissues and adjacent normal tissues/HCT116, HT-29, LoVo, SW480, SW620, NCM460 | HNF4α/LINC00511/IL24 axis | HNF4α and IL24 | The proliferative, spreading and aggressive features of CRC cells are lowered by LINC00511 reduction, that eventually reduces tumorigenicity of CRC. | Lu et al. (2021) |
| Upregulated/Oncogene | 120 TNTPs/SW480, SW620, HCT16, HT29, NCM460 | LINC00511-mediated microRNA (miR)-625-5p/WEE1 axis | miRNA-625-5p/WEE1 | By suppressing WEE1 and restoring miR-625-5p, downregulated LINC00511 prevents the carcinogenesis of CC, establishing a fundamental standard for CC-targeted treatment | Qian et al. (2022) | |
| Upregulated/Oncogene | 12 TNTPs/HT-29, HCT8, HCE8693, SW620, NCM460 | LINC00511/miR-29c-3p/NFIA axis | miR-29c-3p/NFIA | By inhibiting the LINC00511/miR-29c-3p/NFIA axis, LINC00511 assisted in the onset of CRC, proposing that LINC00511 could be a viable therapeutic target. | Hu et al. (2020b) | |
| Glioblastoma (GBM) | Upregulated/Oncogene | 160 TNTPs/U87, A172, U138, U251, U373, LN‐18, T98G, Human HEK293T | Wnt/β-catenin signaling | miR‐126‐5p | In GBM cells, LINC00511 controlled Wnt/Catenin stimulation by functioning as a molecular sponge for miR-126-5p. It stated that LINC00511 could operate as a marker for the treatment of GBM. | Wang et al. (2021) |
| Upregulated/Oncogene | 36 GBM tissues and 8 non-tumour brain tissues (NBT)/U87, LN229, U251, A172, 293T | LINC00511/miR‐524‐5p/YB1/ZEB1 axis | miR‐524‐5p/YB1 | By boosting EMT, the LINC00511/miR524-5p/YB1/ZEB1 positive feedback loop might encourage GBM cell motility and infiltration. LINC00511 could be a viable therapeutic target for GBM sufferers | Du et al. (2020) | |
| Esophageal Cancer (ECa) | Upregulated/Oncogene | - | - | miR-150-5p | By attaching to miR-150-5p and sponging this miRNA, LINC00511 controls the creation of cancerous cells and, could be a treatment option for ECa | Sun et al. (2020a) |
| Cervical Cancer (CC) | Upregulated/Oncogene | - | LINC00511/miR-497-5p/MAPK1 axis | miR-497-5p/MAPK1 | Overexpression of LINC00511 boosted CC cell growth, motility and infiltration, whereas LINC00511 reduction had the opposite effects | Lu et al. (2022) |
| Upregulated/Oncogene | 92 cervical cancer tissues and 40 adjacent normal tissues/SiHa, HeLa, C33A, Caski, Ect1/E6E7 | - | - | In cervical cancer sufferers, high LINC00511 transcription is linked to clinical deterioration. The growth, motility and infiltration of tumor cells are restricted by LINC00511 suppression | Yu et al. (2019) | |
| Upregulated/Oncogene | 40 TNTPs/HT29, LOVO, SW620, SW480 | LINC00511/miR-153-5p/HIF-1α axis | miR-153-5p/HIF-1α | A crucial part of the CRC carcinogenesis is played by LINC00511. HIF-1α/LINC00511/miR-153-5p might be used as a therapeutic target in CRC. | Sun et al. (2020b) | |
| Upregulated/Oncogene | 19 TNTPs/SiHa, CaSki, C33A, HUCEC | LINC00511/miR-324-5p/DRAM1 axis | miR-324-5p/DRAM1 | The miR-324-5p/DRAM1 axis is regulated by LINC00511, acting as a ceRNA which, promotes the progression of both HPV-negative and HPV-positive cervical cancer | Zhang et al. (2020) | |
| Upregulated/Oncogene | 84 CC patients/PTX-resistant Hela/PTX | - | - | Suppression of LINC00511 may lessen CC cell motility and infiltration as well as paclitaxel tolerance, and may boost cell death in CC cells. LINC00511 suppression offers CC a brand-new treatment option | Mao et al. (2019) | |
| Upregulated/Oncogene | 47 TNTPs/SiHa, CaSki, C33A, ME180, HeLa, NCECs | - | RXRA or PLD1 | In CC, LINC00511 promotes the production of PLD1, which is controlled by RXRA. It could be a viable indicator for the therapy of CC. | Shi et al. (2020) | |
| Cervical Squamous Carcinoma (CESC) | Upregulated/Oncogene | 115 cases of CESC, 79 cases of cervical intraepithelial neoplasia and 101 healthy controls | - | - | A diagnostic model consisting of CCAT2 and LINC01133 has exhibited significant clinical utility for the identification of cervical intraepithelial neoplasia in both healthy individuals and patients. The serum concentrations of CCAT2, LINC01133 and LINC00511 could be used as effective non-invasive indicators for the diagnosis of CESC. | Wang et al. (2020b) |
| Clear Cell Renal Cell Carcinoma (ccRCC) | Upregulated/Oncogene | 49 TNTPs/HK-2, A498, 786-O, ACHN, Caki-2 | LINC00511/miR-625/CCND1 pathway | miRNA-625/cyclin D1 | As a ceRNA, LINC00511 controls the transcription of CCND1 in ccRCC via sponging miR-625. As a result, the LINC00511/miR-625/CCND1 pathway could offer ccrCC patients a prospective treatment approach | Deng et al. (2019) |
| Bladder Cancer (BcA) | Upregulated/Oncogene | 47 TNTPs/TCCSUP, SW780 | LINC00511/miR-143-3p/PCMT1 axis | miR-143-3p/PCMT1 | By suppressing the production of miR-143-3p and promoting the production of PCMT1, LINC00511s molecular mechanism may prevent bladder cancer cells from proliferating and invading. A novel target for bladder cancer treatment may be offered by LINC00511 | Dong et al. (2021) |
| Upregulated/Oncogene | 45 TNTPs/SV-HUC-1, BIU87, T24, 5637 | Wnt/β-catenin signaling pathway | miR-15a-3p | By inhibiting the Wnt/β-catenin signaling pathway activity, LINC00511 suppression decreases bladder cancer cells ability to proliferate and increases their likelihood of dying. LINC00511 could also be a putative bladder cancer indicator and possible therapeutic target. | Li et al. (2018) | |
| Tongue Squamous Cell Carcinoma (TSCC) | Upregulated/Oncogene | Tca-8113 | LINC00511/miR-765/LAMC2 axis | miR-765/LAMC2 | By sponging miR-765 with ceRNA, LINC00511 increases the production of LAMC2. the ceRNA regulation network contributes to new knowledge about the pathophysiology of TSCC and given information on how to take advantage of the emerging area of lncRNA-directed treatment for TSCC. | Ding et al. (2018) |
| Non-small Cell Lung Cancer (NSCLC) | Upregulated/Oncogene | 67 patients/16HBE, A549, NCIH1299, NCIH1650, NCIH 1975, NCIH460 | LINC00511/miR-625-5p/GSPT1 axis | miR-625-5p/GSPT1 | By targeting miR-625-5p/GSPT1, LINC00511 boosts NSCLC cell growth, infiltration and motility. LINC00511 is a possible diagnostic indicator and treatment option for NSCLC. | Cheng et al. (2021) |
| Upregulated/Oncogene | 57 TNTPs | - | EZH2 and LSD1/LATS2 and KLF2 | Apoptosis is triggered in NSCLC cells when LINC00511 is knocked down, although this reduces the capability of the cells to spread and infiltrate | Zhu et al. (2019) | |
| Upregulated/Oncogene | 62 stage I NSCLC patients and the age- and gender-matched healthy controls | LINC00511/miR-98-5p/TGFBR1 axis | miR-98-5p/TGFBR1 | In NSCLC, LINC00511 quantities were raised, which may contribute to distant postoperative recurrence of NSCLC and enhance NSCLC cell growth, motility and penetration by targeting and controlling the miR-98-5p/TGFBR1 axis | Li et al. (2022) | |
| Upregulated/Oncogene | 40 TNTPs/A549, H522, A549/DDP, H522/DDP, BEAS-2B | LINC00511/miR-625/LRRC8E pathway | miR-625/LRRC8E | LINC00511 enhanced LRRC8E production by downregulating miR-625 to boost DDP tolerance in NSCLC. A viable therapeutic target to reduce DDP tolerance in NSCLC is LINC00511 | Liu et al. (2022) | |
| Upregulated/Oncogene | 124 TNTPs/A549, SK-MES-1, H1299, 95D, H460, H520, H1975, H157, SK-LU-1, SPC-A-1, 16HBE | - | EZH2 and p57 | In NSCLC, LINC00511 is clinically, physiologically and molecularly oncogenic | Sun et al. (2016) | |
| Pancreatic Cancer (PC) | Upregulated/Oncogene | 91 TNTPs/BxPC-3, CFPAC-1, PANC-1, SW 1990, MIAPaCa-2, HPDE6-C7 | LINC00511/miR-370-5p/p21 Axis | miR-370-5p/p21, Snail, and ZEB1 | The LINC00511/miR-370-5p/p21 promoter region axis was responsible for the suppressive impact of DET (deoxyelephantopin) on the growth and spread of PC cells | Ji et al. (2022) |
| Pancreatic Ductal Adenocarcinoma (PDAC) | Upregulated/Oncogene | 140 TNTPs, PANC‐1, MIA PaCa‐2, Capan‐2, SW 1990, ASPC‐1, BxPC‐3, HPDE6 | LINC005/hsa‐miR29b‐3p/VEGFA axis | miR‐29b‐3p/VEGFA | The etiology of PDAC is profoundly influenced by the new lncRNA LINC00511. LINC00511 is a unique predictive indicator that can forecast the clinical outcomes of PDAC sufferers following surgery and could be used as a treatment option for PDAC. | Zhao et al. (2018) |
| Thyroid Carcinoma (TC) | Upregulated/Oncogene | TPC-1, BCPAP, IHH-4, Nthy-ori 3–1 | JAK2/STAT3 signaling pathway and LINC00511/TAF1/JAK2 axis | TAF1 and JAK2 | Through TAF1-mediated JAK2/STAT3 signaling, enhanced expression of LINC00511 increased the radiosenitivity of TC cells. The potential biomarker function of LINC00511 in the management of TC was shown by the recent research | Chen et al. (2019b) |
| Ovarian Cancer (OC) | Upregulated/Oncogene | CAOV3, OVCAR3, SKOV3, UWB1.289 | - | miR-424-5p and miR-370-5p/ESR1 | With the suppression of cell death, upregulated LINC00511 boosted the vitality, motility and penetration of CAOV3 cells. The disruption of miR-424-5p and miR-370-5p is likely responsible for these actions that promote malignancy | Wang et al. (2019b) |
| Upregulated/Oncogene | SKOV3, SNU840 | - | EZH2 and P21 | The growth of OC cells is slowed by LINC00511 silencing. This information may offer a valuable lncRNA as a predictive indicator and possible treatment option | Deng et al. (2019) |
Dysregulation of LINC00511 in different cancers (TNTP: tumor and non-tumor pairs of tissues).
Transcriptional regulation of LINC00511
Investigations in the Hormonizome database (Rouillard et al., 2016) indicated that 18 transcription factors (CTCF, EP300, ESR1, EZH2, FOXA1, GATA3, H2AFZ, MAX, MYC, NFIC, NR2F2, NR3C1, POLR2A, RAD21, TCF12, TEAD4, YY1, and ZBTB7A) possibly bind to the promoter of LINC00511 gene based on ChIP-seq data from the ENCODE Transcription Factor Target dataset.
LINC00511 related pathways and functions.
Based on lncHUB database (https://maayanlab.cloud/lnchub/), 10 KEGG pathways with the highest Z-score in which LINC00511 is predicted to be involved include glycosphingolipid biosynthesis, bacterial invasion of epithelial cells, basal cell carcinoma, central carbon metabolism in cancer, notch signaling pathway, RNA polymerase, DNA replication, cell cycle, bladder cancer and mismatch repair. Additionally, 10 gene ontology (GO) terms with the highest Z-score that are associated with LINC00511 include regulation of hydrogen peroxide-induced cell death (GO:1903205), negative regulation of response to reactive oxygen species (GO:1901032), protein heterotetramerization (GO:0051290), viral release from host cell (GO:0019076), exit from host cell (GO:0035891), signal complex assembly (GO:0007172), regulation of striated muscle tissue development (GO:0016202), regulation of myelination (GO:0031641), positive regulation of kidney development (GO:0090184) and regulation of proteolysis (GO:0030162). Also, IGSF11, PHLPP1, CPOX, SOX2, PACC1, SOX21, TMPRSS5, HEY1, MARCKS, KCTD5, OLIG2, ATAT1, CDK5R1, BCAN and BAALC are 15 genes with the highest Z-score predicted to be co-expressed with LINC00511.
LINC00511 interactions with miRNAs and other molecules
Based on RNAInter (RNA Interactome Database) (Kang et al., 2022), LINC00511 has interactions with hsa-miR-29b-3p, hsa-miR-765, hsa-mir-150, miR-1231, TFAP2A-AS2, hsa-miR-185-3p, hsa-miR-29b-1-5p, hsa-miR-29c-3p, RAD51-AS1 and EZH2 with score ≥0.1. Also, based on LncRNA2Target v3.0 (Cheng et al., 2019), LINC00511 interactions with miRNAs has been showed in Table 5.
TABLE 5
| Target gene | LncRNA experiment | Tissue | Cell line | Disease state | Reference |
|---|---|---|---|---|---|
| MIR29B1 | Luciferase reporter assays, RNA immunoprecipitation | Pancreatic cancer | PANC-1, MIA PaCa-2, Capan-2, SW 1990, ASPC-1, BxPC-3 | Pancreatic cancer | Zhao et al. (2018) |
| MIR765 | Dual luciferase reporter assays | NA | Tca-8113 | Tongue squamous cell carcinoma | Ding et al. (2018) |
| MIR524 | Dual-luciferase gene reporter assay, RNA immunoprecipitation (RIP) | Brain | U87, LN229, U251, A172, 293T | Glioblastoma Multiforme | Du et al. (2020) |
| miR-124-3p | Luciferase assay | GC tissue | GES-1, MGC, HGC, MKN25, MKN28 | Gastric cancer | Huang et al. (2020) |
| MIR150 | Luciferase reporter assay | Breast | MDA-MB-231, MCF-7 | Breast Cancer | Shi et al. (2021) |
LINC00511 interactions with miRNAs.
Impact of LINC00511 dysregulation on clinical outcome of patients with cancers
We investigated the survival rate caused by LINC00511 in different cancers using ualcan database (Chandrashekar et al., 2017). This database performs survival analysis using TCGA data. The difference was statistically significant with a log-rank p-value less than 0.05. As a result, LINC00511 has an effect on the survival rate of patients with adrenocortical carcinoma (ACC), breast invasive carcinoma (BRCA), kidney renal clear cell carcinoma (KIRC), acute myeloid leukemia (LAML), liver hepatocellular carcinoma (LIHC), Mesothelioma (MESO), pheochromocytoma and paraganglioma (PCPG) and sarcoma (SARC) (Figure 3). While in patients with LAML, overexpression of this lncRNA is associated with better clinical outcome, in other types of cancers, its upregulation is associated with lower survival.
FIGURE 3
Discussion
LINC00511 is a lincRNA being over-expressed in a variety of human tumors and cancer cell lines. Except for a single study in osteosarcoma (Qiao et al., 2020), other studies in this type of cancer and other cancers have reported upregulation of LINC00511 in tumoral tissues compared with their non-tumoral counterparts. Dysregulation of LINC00511 affects cancer pathogenesis through increasing cell proliferation and inhibiting cell apoptosis. It can also increase activity of several cancer-promoting signaling pathways.
A previous meta-analysis has reported association between over-expression of LINC00511 and poor prognosis in different cancers in terms of overall, progression-free or relapse-free survival times (Agbana et al., 2020). Moreover, upregulation of this lncRNA has been associated with larger tumor size, recurrent disorder and metastasis to lymph nodes or distant organs (Agbana et al., 2020).
Mechanistically, LINC00511 can act as a molecular sponge for a variety of miRNAs regulating their targets. miR-185-3p/E2F1, miR-150/MMP13, miR-29c/CDK6, miR-185/STXBP4, miR-573/GSDMC, miR‐195‐5p/SOX4, miR-124-3p/PDK4, miR-625-5p/NFIX, miR-124-3p/EZH2, miR-625-5p/STAT3, miR-29b/KDM2A, miR-195/EYA1, miR-185-3p/E2F1, miRNA-618/MAEL, miR-195-5p/LRRK1, miR-15a-5p/AEBP1, miR‐124‐3p/CCND2, miRNA-625-5p/WEE1, miR-29c-3p/NFIA, miR-150-5p/TADA1, miR‐524‐5p/YB1, miR-625-5p/PKM2, miR-195-5p/GCNT3, miR-182-3p/BIRC5, miR-218-5p/COL1A1, miR-497-5p/MAPK1, miR-153-5p/HIF-1α, miR-324-5p/DRAM1, miR-625/cyclin D1, miR-143-3p/PCMT1, miR-765/LAMC2, miR-625-5p/GSPT1, miR-98-5p/TGFBR1, miR-625/LRRC8E, miR-370-5p/p21, miR‐29b‐3p/VEGFA and miR-370-5p/ESR1 are examples of miRNA/mRNA axes that are regulated by LINC00511. Molecular axes being regulated by LINC00511 in more than one type of cancer represent better targets for design of anti-cancer therapies since they can be applied in a wider range of malignancies. Therefore, identification of the impact of above-mentioned molecular axes in the progression of different types of cancer is an important step in design of novel therapeutics.
LINC00511 can induce stemness in cancers and facilitate tumor progression and metastasis (Lu et al., 2018). Therefore, LINC00511-modifying modalities can be used as possible strategies for defeating cancer metastasis.
The prognostic role of over-expression of LINC00511 in different cancers has been evaluated thoroughly by various research groups indicating its important effects on survival of affected individuals. Future studies should assess its expression in biofluids to provide a non-invasive route for cancer diagnosis and patients’ follow-up.
Statements
Author contributions
MT designed and supervised the study. SG-F wrote the draft and revised it. AS, BH, and SA collected the data and designed the figures and tables. All the authors read the submitted version and approved it.
Funding
This study was Financially supported by Shahid Beheshti University of Medical Sciences.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AgbanaY. L.AbiM. E.NiY.XiongG.ChenJ.YunF.et al (2020). LINC00511 as a prognostic biomarker for human cancers: A systematic review and meta-analysis. BMC Cancer20 (1), 682. 10.1186/s12885-020-07188-3
2
AzadbakhtN.DoostiA.JamiM. S. (2022). CRISPR/Cas9-mediated LINC00511 knockout strategies, increased apoptosis of breast cancer cells via suppressing antiapoptotic genes. Biol. Proced. Online24 (1), 8. 10.1186/s12575-022-00171-1
3
ChandrashekarD. S.BashelB.BalasubramanyaS. A. H.CreightonC. J.Ponce-RodriguezI.ChakravarthiB.et al (2017). Ualcan: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia19 (8), 649–658. 10.1016/j.neo.2017.05.002
4
ChenY.BaoC.ZhangX.LinX.FuY. (2019). Knockdown of LINC00511 promotes radiosensitivity of thyroid carcinoma cells via suppressing JAK2/STAT3 signaling pathway. Cancer Biol. Ther.20 (9), 1249–1257. 10.1080/15384047.2019.1617569
5
ChenZ.WuH.ZhangZ.LiG.LiuB. (2019). LINC00511 accelerated the process of gastric cancer by targeting miR-625-5p/NFIX axis. Cancer Cell Int.19, 351. 10.1186/s12935-019-1070-0
6
ChengL.WangP.TianR.WangS.GuoQ.LuoM.et al (2019). LncRNA2Target v2.0: A comprehensive database for target genes of lncRNAs in human and mouse. Nucleic Acids Res.47 (D1), D140–D144. 10.1093/nar/gky1051
7
ChengY.WangS.MuX. (2021). Long non-coding RNA LINC00511 promotes proliferation, invasion, and migration of non-small cell lung cancer cells by targeting miR-625-5p/GSPT1. Transl. Cancer Res.10 (12), 5159–5173. 10.21037/tcr-21-1468
8
CuiN.SunQ.LiuH.LiL.GuoX.ShiY.et al (2021). Long non-coding RNA LINC00511 regulates the expression of microRNA-625-5p and activates signal transducers and activators of transcription 3 (STAT3) to accelerate the progression of gastric cancer. Bioengineered12 (1), 2915–2927. 10.1080/21655979.2021.1940611
9
DengH.HuangC.WangY.JiangH.PengS.ZhaoX. (2019). LINC00511 promotes the malignant phenotype of clear cell renal cell carcinoma by sponging microRNA-625 and thereby increasing cyclin D1 expression. Aging (Albany NY)11 (16), 5975–5991. 10.18632/aging.102156
10
DingJ.YangC.YangS. (2018). LINC00511 interacts with miR-765 and modulates tongue squamous cell carcinoma progression by targeting LAMC2. J. Oral Pathol. Med.47 (5), 468–476. 10.1111/jop.12677
11
DongL. M.ZhangX. L.MaoM. H.LiY. P.ZhangX. Y.XueD. W.et al (2021). LINC00511/miRNA-143-3p modulates apoptosis and malignant phenotype of bladder carcinoma cells via PCMT1. Front. Cell Dev. Biol.9, 650999. 10.3389/fcell.2021.650999
12
DuX.TuY.LiuS.ZhaoP.BaoZ.LiC.et al (2020). LINC00511 contributes to glioblastoma tumorigenesis and epithelial-mesenchymal transition via LINC00511/miR-524-5p/YB1/ZEB1 positive feedback loop. J. Cell Mol. Med.24 (2), 1474–1487. 10.1111/jcmm.14829
13
FangS.ZhangL.GuoJ.NiuY.WuY.LiH.et al (2018). NONCODEV5: A comprehensive annotation database for long non-coding RNAs. Nucleic acids Res.46 (D1), D308–D314. 10.1093/nar/gkx1107
14
Ghafouri-FardS.AbakA.ShooreiH.MohaqiqM.MajidpoorJ.SayadA.et al (2021). Regulatory role of microRNAs on PTEN signaling. Biomed. Pharmacother.133, 110986. 10.1016/j.biopha.2020.110986
15
Ghafouri-FardS.ShooreiH.TaheriM. (2020). Non-coding RNAs are involved in the response to oxidative stress. Biomed. Pharmacother.127, 110228. 10.1016/j.biopha.2020.110228
16
GuoW.YuQ.ZhangM.LiF.LiuY.JiangW.et al (2019). Long intergenic non-protein coding RNA 511 promotes the progression of osteosarcoma cells through sponging microRNA 618 to upregulate the expression of maelstrom. Aging (Albany NY)11 (15), 5351–5367. 10.18632/aging.102109
17
HuW. Y.WeiH. Y.LiK. M.WangR. B.XuX. Q.FengR. (2020). LINC00511 as a ceRNA promotes cell malignant behaviors and correlates with prognosis of hepatocellular carcinoma patients by modulating miR-195/EYA1 axis. Biomed. Pharmacother.121, 109642. 10.1016/j.biopha.2019.109642
18
HuY.ZhangY.DingM.XuR. (2020). LncRNA LINC00511 acts as an oncogene in colorectal cancer via sponging miR-29c-3p to upregulate NFIA. Onco Targets Ther.13, 13413–13424. 10.2147/OTT.S250377
19
HuangH. G.TangX. L.HuangX. S.ZhouL.HaoY. G.ZhengY. F. (2020). Long noncoding RNA LINC00511 promoted cell proliferation and invasion via regulating miR-124-3p/EZH2 pathway in gastric cancer. Eur. Rev. Med. Pharmacol. Sci.24 (8), 4232–4245. 10.26355/eurrev_202004_21003
20
HussenB. M.KhederR. K.AbdullahS. T.HidayatH. J.RahmanH. S.SalihiA.et al (2022). Functional interplay between long non-coding RNAs and Breast CSCs. Cancer Cell Int.22 (1), 233. 10.1186/s12935-022-02653-4
21
JiD.HouL.XieC.FengH.BaoD.TengY.et al (2022). Deoxyelephantopin suppresses pancreatic cancer progression in vitro and in vivo by targeting linc00511/miR-370-5p/p21 promoter Axis. J. Oncol.2022, 3855462. 10.1155/2022/3855462
22
KangJ.TangQ.HeJ.LiL.YangN.YuS.et al (2022). RNAInter v4.0: RNA interactome repository with redefined confidence scoring system and improved accessibility. Nucleic Acids Res.50 (D1), D326–D332. 10.1093/nar/gkab997
23
KaragkouniD.ParaskevopoulouM. D.TastsoglouS.SkoufosG.KaravangeliA.PierrosV.et al (2020). DIANA-LncBase v3: Indexing experimentally supported miRNA targets on non-coding transcripts. Nucleic Acids Res.48 (D1), D101–D110. 10.1093/nar/gkz1036
24
LiC.LiZ.YiH.LiuZ. (2022). IncRNA Linc00511 upregulation elevates TGFBR1 and participates in the postoperative distant recurrence of non-small-cell lung cancer by targeting miR-98-5p. Crit. Rev. Eukaryot. Gene Expr.32 (5), 1–10. 10.1615/CritRevEukaryotGeneExpr.2022039498
25
LiC.LiuH.YangJ.YangJ.YangL.WangY.et al (2019). Long noncoding RNA LINC00511 induced by SP1 accelerates the glioma progression through targeting miR-124-3p/CCND2 axis. J. Cell Mol. Med.23 (6), 4386–4394. 10.1111/jcmm.14331
26
LiJ.LiY.MengF.FuL.KongC. (2018). Knockdown of long non-coding RNA linc00511 suppresses proliferation and promotes apoptosis of bladder cancer cells via suppressing Wnt/β-catenin signaling pathway. Biosci. Rep.38 (4). 10.1042/bsr20171701
27
LiS.GuoW.GengH.WangC.YangS.XuX. (2020). LINC00511 exacerbated T-cell acute lymphoblastic leukemia via miR-195-5p/LRRK1 axis. Biosci. Rep.40 (5). 10.1042/BSR20193631
28
LiuB.ZhouF.LiuH.WangY.WangJ.RenF.et al (2022). Knockdown of LINC00511 decreased cisplatin resistance in non-small cell lung cancer by elevating miR-625 level to suppress the expression of leucine rich repeat containing eight volume-regulated anion channel subunit E. Hum. Exp. Toxicol.41, 9603271221089000. 10.1177/09603271221089000
29
LiuC.XuY.LiuX.FuY.ZhuK.NiuZ.et al (2021). Upregulation of LINC00511 expression by DNA hypomethylation promotes the progression of breast cancer. Gland. Surg.10 (4), 1418–1430. 10.21037/gs-21-84
30
LiuL.ZhuY.LiuA. M.FengY.ChenY. (2019). Long noncoding RNA LINC00511 involves in breast cancer recurrence and radioresistance by regulating STXBP4 expression via miR-185. Eur. Rev. Med. Pharmacol. Sci.23 (17), 7457–7468. 10.26355/eurrev_201909_18855
31
LiuZ.TaoB.LiL.LiuP.XiaK.ZhongC. (2021). LINC00511 knockdown suppresses glioma cell malignant progression through miR-15a-5p/AEBP1 axis. Brain Res. Bull.173, 82–96. 10.1016/j.brainresbull.2021.05.010
32
LuG.LiY.MaY.LuJ.ChenY.JiangQ.et al (2018). Long noncoding RNA LINC00511 contributes to breast cancer tumourigenesis and stemness by inducing the miR-185-3p/E2F1/Nanog axis. J. Exp. Clin. Cancer Res.37 (1), 289. 10.1186/s13046-018-0945-6
33
LuM.GaoQ.WangY.RenJ.ZhangT. (2022). LINC00511 promotes cervical cancer progression by regulating the miR-497-5p/MAPK1 axis. Apoptosis27, 800–811. 10.1007/s10495-022-01768-3
34
LuY.YuY.LiuF.HanY.XueH.SunX.et al (2021). LINC00511-dependent inhibition of IL-24 contributes to the oncogenic role of HNF4α in colorectal cancer. Am. J. Physiol. Gastrointest. Liver Physiol.320 (3), G338–G350. 10.1152/ajpgi.00243.2020
35
MahmoudM. M.SanadE. F.ElshimyR. A. A.HamdyN. M. (2021). Competitive endogenous role of the linc00511/miR-185-3p Axis and miR-301a-3p from liquid biopsy as molecular markers for breast cancer diagnosis. Front. Oncol.11, 749753. 10.3389/fonc.2021.749753
36
MaoB. D.XuP.XuP.ZhongY.DingW. W.MengQ. Z. (2019). LINC00511 knockdown prevents cervical cancer cell proliferation and reduces resistance to paclitaxel. J. Biosci.44 (2), 44. 10.1007/s12038-019-9851-0
37
MeléM.MattioliK.MallardW.ShechnerD. M.GerhardingerC.RinnJ. L. (2017). Chromatin environment, transcriptional regulation, and splicing distinguish lincRNAs and mRNAs. Genome Res.27 (1), 27–37. 10.1101/gr.214205.116
38
PengX.LiX.YangS.HuangM.WeiS.MaY.et al (2021). LINC00511 drives invasive behavior in hepatocellular carcinoma by regulating exosome secretion and invadopodia formation. J. Exp. Clin. Cancer Res.40 (1), 183. 10.1186/s13046-021-01990-y
39
QianX.JiangC.ZhuZ.HanG.XuN.YeJ.et al (2022). Long non-coding RNA LINC00511 facilitates colon cancer development through regulating microRNA-625-5p to target WEE1. Cell Death Discov.8 (1), 233. 10.1038/s41420-021-00790-9
40
QiaoS.QiK.LiuC.XuC.MaJ.XuX.et al (2020). Long intergenic non-coding RNA 511 correlates with improved prognosis, and hinders osteosarcoma progression both in vitro and in vivo. J. Clin. Lab. Anal.34 (5), e23164. 10.1002/jcla.23164
41
RouillardA. D.GundersenG. W.FernandezN. F.WangZ.MonteiroC. D.McDermottM. G.et al (2016). The harmonizome: A collection of processed datasets gathered to serve and mine knowledge about genes and proteins. Database (Oxford)2016, baw100. 10.1093/database/baw100
42
ShiG.ChengY.ZhangY.GuoR.LiS.HongX. (2021). Long non-coding RNA LINC00511/miR-150/MMP13 axis promotes breast cancer proliferation, migration and invasion. Biochim. Biophys. Acta Mol. Basis Dis.1867 (3), 165957. 10.1016/j.bbadis.2020.165957
43
ShiY.LiuM.HuangY.ZhangJ.YinL. (2020). Promotion of cell autophagy and apoptosis in cervical cancer by inhibition of long noncoding RNA LINC00511 via transcription factor RXRA-regulated PLD1. J. Cell Physiol.235 (10), 6592–6604. 10.1002/jcp.29529
44
StatelloL.GuoC-J.ChenL-L.HuarteM. (2021). Gene regulation by long non-coding RNAs and its biological functions. Nat. Rev. Mol. Cell Biol.22 (2), 96–118. 10.1038/s41580-020-00315-9
45
SunC. B.WangH. Y.HanX. Q.LiuY. N.WangM. C.ZhangH. X.et al (2020). LINC00511 promotes gastric cancer cell growth by acting as a ceRNA. World J. Gastrointest. Oncol.12 (4), 394–404. 10.4251/wjgo.v12.i4.394
46
SunC. C.LiS. J.LiG.HuaR. X.ZhouX. H.LiD. J. (2016). Long intergenic noncoding RNA 00511 acts as an oncogene in non-small-cell lung cancer by binding to EZH2 and suppressing p57. Mol. Ther. Nucleic Acids5 (11), e385. 10.1038/mtna.2016.94
47
SunK.ChenR. X.LiJ. Z.LuoZ. X. (2022). LINC00511/hsa-miR-573 axis-mediated high expression of Gasdermin C associates with dismal prognosis and tumor immune infiltration of breast cancer. Sci. Rep.12 (1), 14788. 10.1038/s41598-022-19247-9
48
SunS.XiaC.XuY. (2020). HIF-1α induced lncRNA LINC00511 accelerates the colorectal cancer proliferation through positive feedback loop. Biomed. Pharmacother.125, 110014. 10.1016/j.biopha.2020.110014
49
WangD.LiuK.ChenE. (2020). LINC00511 promotes proliferation and invasion by sponging miR-515-5p in gastric cancer. Cell Mol. Biol. Lett.25, 4. 10.1186/s11658-020-0201-x
50
WangK.ZhuG.BaoS.ChenS. (2019). Long non-coding RNA LINC00511 mediates the effects of ESR1 on proliferation and invasion of ovarian cancer through miR-424-5p and miR-370-5p. Cancer Manag. Res.11, 10807–10819. 10.2147/CMAR.S232140
51
WangQ.MaoX.LuoF.WangJ. (2021). LINC00511 promotes gastric cancer progression by regulating SOX4 and epigenetically repressing PTEN to activate PI3K/AKT pathway. J. Cell Mol. Med.25 (19), 9112–9127. 10.1111/jcmm.16656
52
WangR. P.JiangJ.JiangT.WangY.ChenL. X. (2019). Increased long noncoding RNA LINC00511 is correlated with poor prognosis and contributes to cell proliferation and metastasis by modulating miR-424 in hepatocellular carcinoma. Eur. Rev. Med. Pharmacol. Sci.23 (8), 3291–3301. 10.26355/eurrev_201904_17691
53
WangW. J.WangD.ZhaoM.SunX. J.LiY.LinH.et al (2020). Serum lncRNAs (CCAT2, LINC01133, LINC00511) with squamous cell carcinoma antigen panel as novel non-invasive biomarkers for detection of cervical squamous carcinoma. Cancer Manag. Res.12, 9495–9502. 10.2147/CMAR.S259586
54
WangY.MeiX.SongW.WangC.QiuX. (2022). LncRNA LINC00511 promotes COL1A1-mediated proliferation and metastasis by sponging miR-126-5p/miR-218-5p in lung adenocarcinoma. BMC Pulm. Med.22 (1), 272. 10.1186/s12890-022-02070-3
55
WuY.LiL.WangQ.ZhangL.HeC.WangX.et al (2020). LINC00511 promotes lung squamous cell carcinoma proliferation and migration via inhibiting miR-150-5p and activating TADA1. Transl. Lung Cancer Res.9 (4), 1138–1148. 10.21037/tlcr-19-701
56
XiangJ.GuanY.BhandariA.XiaE.WenJ.WangO. (2020). LINC00511 influences cellular proliferation through cyclin-dependent kinases in papillary thyroid carcinoma. J. Cancer11 (2), 450–459. 10.7150/jca.35364
57
XuJ.ChenG.ZhangY.HuangZ.ChengX.GuH.et al (2020). LINC00511 promotes osteosarcoma tumorigenesis and invasiveness through the miR-185-3p/E2F1 Axis. Biomed. Res. Int.2020, 1974506. 10.1155/2020/1974506
58
XueJ.ZhangF. (2020). LncRNA LINC00511 plays an oncogenic role in lung adenocarcinoma by regulating PKM2 expression via sponging miR-625-5p. Thorac. Cancer11 (9), 2570–2579. 10.1111/1759-7714.13576
59
YanL.WuX.LiuY.XianW. (2018). LncRNA Linc00511 promotes osteosarcoma cell proliferation and migration through sponging miR-765. J. Cell Biochem.120, 7248–7256. 10.1002/jcb.27999
60
YangF.LyuS.DongS.LiuY.ZhangX.WangO. (2016). Expression profile analysis of long noncoding RNA in HER-2-enriched subtype breast cancer by next-generation sequencing and bioinformatics. Onco Targets Ther.9, 761–772. 10.2147/OTT.S97664
61
YuC. L.XuX. L.YuanF. (2019). LINC00511 is associated with the malignant status and promotes cell proliferation and motility in cervical cancer. Biosci. Rep.39 (9). 10.1042/BSR20190903
62
ZhangJ.SuiS.WuH.ZhangJ.ZhangX.XuS.et al (2019). The transcriptional landscape of lncRNAs reveals the oncogenic function of LINC00511 in ER-negative breast cancer. Cell Death Dis.10 (8), 599–602. 10.1038/s41419-019-1835-3
63
ZhangX.WangY.ZhaoA.KongF.JiangL.WangJ. (2020). Long non-coding RNA LINC00511 accelerates proliferation and invasion in cervical cancer through targeting miR-324-5p/DRAM1 Axis. Onco Targets Ther.13, 10245–10256. 10.2147/OTT.S255067
64
ZhangY.XiaoP.HuX. (2022). LINC00511 enhances LUAD malignancy by upregulating GCNT3 via miR-195-5p. BMC Cancer22 (1), 389. 10.1186/s12885-022-09459-7
65
ZhaoX.LiuY.LiZ.ZhengS.WangZ.LiW.et al (2018). Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma. J. Cell Mol. Med.22 (1), 655–667. 10.1111/jcmm.13351
66
ZhaoY.ChenX.JiangJ.WanX.WangY.XuP. (2020). Epigallocatechin gallate reverses gastric cancer by regulating the long noncoding RNA LINC00511/miR-29b/KDM2A axis. Biochim. Biophys. Acta Mol. Basis Dis.1866 (10), 165856. 10.1016/j.bbadis.2020.165856
67
ZhuF. Y.ZhangS. R.WangL. H.WuW. D.ZhaoH. (2019). LINC00511 promotes the progression of non-small cell lung cancer through downregulating LATS2 and KLF2 by binding to EZH2 and LSD1. Eur. Rev. Med. Pharmacol. Sci.23 (19), 8377–8390. 10.26355/eurrev_201910_19149
68
ZhuZ.ShiY.GongX.LiJ.ZhangM. (2022). LINC00511 knockdown suppresses resistance to cisplatin in lung adenocarcinoma by interacting with miR-182-3p and BIRC5. Mol. Biotechnol.64 (3), 252–262. 10.1007/s12033-021-00400-0
Summary
Keywords
LINC00511, cancer, biomarker, expression, diagnostic
Citation
Ghafouri-Fard S, Safarzadeh A, Hussen BM, Taheri M and Ayatollahi SA (2023) A review on the role of LINC00511 in cancer. Front. Genet. 14:1116445. doi: 10.3389/fgene.2023.1116445
Received
05 December 2022
Accepted
05 April 2023
Published
14 April 2023
Volume
14 - 2023
Edited by
Yujing Li, Emory University, United States
Reviewed by
Yulin Jin, Emory University, United States
Yangping Li, Emory University, United States
Updates
Copyright
© 2023 Ghafouri-Fard, Safarzadeh, Hussen, Taheri and Ayatollahi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mohammad Taheri, mohammad.taheri@uni-jena.de; Seyed Abdulmajid Ayatollahi, majid_ayatollahi@yahoo.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.